Back to Journals » Clinical Epidemiology » Volume 10

Using a chronic hepatitis B Registry to support population-level liver cancer prevention in Sydney, Australia

Authors Robotin MC, Masgoret X, Porwal M, Goldsbury D, Khoo C, George J

Received 13 July 2017

Accepted for publication 31 October 2017

Published 21 December 2017 Volume 2018:10 Pages 41—49

DOI https://doi.org/10.2147/CLEP.S146275

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Professor Vera Ehrenstein

Video abstract presented by Monica C Robotin.

Views: 24

Monica C Robotin,1–3 Ximena Masgoret,1 Mamta Porwal,4 David Goldsbury,5 Chee Khoo,6,7 Jacob George,2,3

1School of Medicine, The University of Notre Dame Australia, Darlinghurst, 2Faculty of Medicine, University of Sydney, Camperdown, 3Storr Liver Center, Westmead Institute for Medical Research, Westmead Hospital, Westmead, 4Australian School of Graduate Management, University of New South Wales, Kensington, 5Cancer Council NSW, Woolloomooloo, 6Royal Australasian College of General Practitioners, Sydney, 7University of Western Sydney, Macarthur, NSW, Australia


Background: Approximately 1% of Australians have chronic hepatitis B (CHB), which disproportionately affects people born in hepatitis B-endemic countries. Currently, approximately half of the people affected remain undiagnosed and antiviral treatment uptake is suboptimal (~5%). This increases the likelihood of developing end-stage disease complications, particularly hepatocellular cancer (HCC), and largely accounts for the significant increases in HCC incidence and mortality in Australia over the last decades. As our previous economic modeling suggested that CHB screening and treatment is cost-effective, we tested the feasibility of a primary care-based model of CHB diagnosis and management to prevent HCC.
Materials and methods: From 2009 to 2016, the B Positive program trialed a CHB screening and management program in an area of high disease prevalence in Sydney, Australia. Trained local primary care providers (general practitioners) screened and managed their CHB patients using a purpose-built CHB Registry and a risk stratification algorithm, which allocated patients to ongoing primary care-based management or specialist referral.
Results: The program enrolled and followed up >1,500 people (25% of the target population). Their median age was 48 years, with most participants being born in China (50%) or Vietnam (32%). The risk stratification algorithm allocated most Registry participants (n=847 or 79%) to primary care-based management, reducing unnecessary specialist referrals. The level of antiviral treatment uptake in Registry patients was 18%, which was the optimal level in this population group.
Conclusion: This pilot program demonstrated that primary care-based hepatitis B diagnosis and management is acceptable to patients and their care providers and significantly increases compliance with treatment guidelines. This would suggest that scaling up access to hepatitis B treatment is achievable and can provide a means to operationalize a population-level approach to CHB management and liver cancer prevention.

Keywords: hepatitis B Registry, primary care, cancer prevention, antiviral treatment, risk stratification

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author: